Arcutis Biotherapeutics, Inc. (ARQT) - What Are Researchers Saying About This Stock?

Arcutis Biotherapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Eight of 10 brokerages rate ARQT a buy and two a hold, with a consensus 12-month price target of $39.75.
  • In its latest quarter, Arcutis reported EPS of $0.06, missing the $0.18 consensus estimate, while revenue of $143.92 million slightly exceeded forecasts.
  • Insiders sold 103,130 shares worth about $3.0 million over the past 90 days; one executive’s sale was made under a pre-arranged plan to cover taxes on vested equity awards.
  • MarketBeat previews top five stocks to own in December.

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $39.75.

ARQT has been the topic of several recent research reports. Needham & Company LLC set a $40.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, November 5th. Jefferies Financial Group restated a "buy" rating and issued a $39.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, November 7th. Morgan Stanley lifted their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald began coverage on shares of Arcutis Biotherapeutics in a report on Thursday, October 15th. They set an "overweight" rating and a $48.00 price target on the stock.

Read Our Latest Stock Report on ARQT

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Terrie Curran sold 38,200 shares of Arcutis Biotherapeutics stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $25.03, for a total transaction of $956,146.00. Following the transaction, the director directly owned 23,526 shares of the company's stock, valued at approximately $588,855.78. The trade was a 61.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Masaru Matsuda sold 40,000 shares of Arcutis Biotherapeutics stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $34.32, for a total value of $1,372,800.00. Following the transaction, the executive vice president directly owned 111,289 shares in the company, valued at $3,819,438.48. The trade was a 26.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 103,130 shares of company stock worth $3,006,478 over the last 90 days. Company insiders own 9.40% of the company's stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARQT. Montanova Capital LLC increased its position in Arcutis Biotherapeutics by 0.9% during the 2nd quarter. Montanova Capital LLC now owns 12,437,000 shares of the company's stock valued at $326,098,000 after purchasing an additional 110,000 shares during the period. BlackRock Inc. bought a new position in Arcutis Biotherapeutics during the 2nd quarter worth approximately $276,502,000. Bank of America Corp DE bought a new position in Arcutis Biotherapeutics during the 2nd quarter worth approximately $78,330,000. American Century Companies Inc. lifted its position in shares of Arcutis Biotherapeutics by 2.6% in the 3rd quarter. American Century Companies Inc. now owns 1,975,939 shares of the company's stock worth $52,224,000 after purchasing an additional 50,908 shares during the period. Finally, Janus Henderson Group PLC lifted its position in shares of Arcutis Biotherapeutics by 1.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company's stock worth $43,684,000 after purchasing an additional 24,505 shares during the period.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $26.36 on Friday. The business's 50-day moving average price is $27.86 and its 200-day moving average price is $25.44. Arcutis Biotherapeutics has a 12 month low of $19.30 and a 12 month high of $34.80. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of 125.52 and a beta of 1.66. The company has a current ratio of 2.92, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. The firm had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. Equities research analysts forecast that Arcutis Biotherapeutics will post 0.28 EPS for the current year.

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.

See Also

Analyst Recommendations for Arcutis Biotherapeutics (NASDAQ:ARQT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arcutis Biotherapeutics Right Now?

Before you consider Arcutis Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.

While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines